Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
EU Decision Time For Teclistamab & Seven Other Drugs; Incyte Withdraws Parsaclisib Filing
Janssen’s bispecific antibody, teclistamab, and Eli Lilly’s potential blockbuster diabetes drug, tirzepatide, are among the products that are this week up for an opinion by the European Medicines Agency on whether they should be approved in the EU.